The transformative impact of BCMA-targeting bispecific antibodies in RRMM

Andrew Yee, MD, Massachusetts General Hospital Cancer Center, Boston, MA, highlights the transformative impact of BCMA-targeting therapies in relapsed/refractory multiple myeloma (RRMM). Dr Yee notes that bispecific antibodies, in particular, offer a significant advantage due to their off-the-shelf availability and feasibility for patients in the community, making them a more accessible treatment option. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.